Literature DB >> 6432916

Deficiency of interleukin-2 production and interleukin-2 receptor expression on peripheral blood leukocytes after phytohemagglutinin stimulation in pemphigus.

V Kermani-Arab, K Hirji, A R Ahmed, J L Fahey.   

Abstract

Peripheral blood mononuclear cells from 22 pemphigus patients with active disease and 30 normal subjects were evaluated for interleukin 2 (IL-2) production and IL-2 receptor expression following stimulation with phytohemagglutinin P (PHA-P). The IL-2 levels were lower in patients compared to corresponding controls and the production was delayed after PHA stimulation. This deficiency was most pronounced in severely affected patients. IL-2 receptor appearance also was lower after PHA stimulation in a small number of patients tested. These results indicate that some cellular immune functions are altered in pemphigus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432916     DOI: 10.1111/1523-1747.ep12263194

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  4 in total

1.  The effect of experimental haemocarbofiltration upon activity of mononuclear cells from normal and autoimmune patients.

Authors:  S A Grando; B T Glukhenky; G N Drannik; A P Kostromin; A B Romanenko
Journal:  Immunology       Date:  1989-01       Impact factor: 7.397

2.  In vitro hepatitis B virus infection of human bone marrow cells.

Authors:  J B Zeldis; H Mugishima; H N Steinberg; E Nir; R P Gale
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

3.  Spontaneous recovery of the decreased expression in vitro of interleukin 2 receptors in rheumatoid arthritis.

Authors:  C Plater-Zyberk; K A Rockett; R N Maini
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

4.  Normalization of defective interleukin 1 and interleukin 2 production in patients with pemphigus vulgaris following chrysotherapy.

Authors:  E Blitstein-Willinger
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.